Interesting that the European Atherosclerosis Society (EAS) twitter account @EASCongress tweeted the other day about the recent Apabetalone manuscript on vascular calcification.

https://twitter.com/EASCongress/status/1098296507214774273?s=20

"Translational Research: Apabetalone downregulates factors and pathways associated with vascular calcification.

(link: http://ow.ly/D1EI30nKK56) ow.ly/D1EI30nKK56 #Atherosclerosis #cardiovascular #thrombosis #arteries #LDL #HDL #heart #cholesterol #EAS2019"

If you look at the recent twitter feed for @EASCongress, it is almost exclusively tweeting stuff related to the upcoming EAS meeting in May 2019. The apabetalone tweet mentioned above used the #EAS2019 hashtag. I think we are still a few weeks away from the mid-March listing of abstracts to be presented at EAS 2019, so no idea yet if Resverlogix is presenting something there or not. 

Dr. Kausik Ray, the BETonMACE clinical steering committee chair, replied to the above tweet "Now just need to see if our CVOT BETonMACE shows benefit this year......." One doc replied to Dr. Ray asking what company had apabetalone in their pipeline and Dr.Ray responded "Resverlogix".

Increased chatter. Buzz around EAS 2019. Interesting......

BearDownAZ